Ponraj Prabakaran
Overview
Explore the profile of Ponraj Prabakaran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1899
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prabakaran P, Gupta A, Rao S, Rajpal D, Wendt M, Qiu Y, et al.
Commun Biol
. 2025 Jan;
8(1):133.
PMID: 39875530
Antibodies, essential components of adaptive immunity, derive their remarkable diversity primarily from V(D)J gene rearrangements, particularly within the heavy chain complementarity-determining region 3 (CDR-H3) where D genes play a major...
2.
Mahendra A, Haque A, Prabakaran P, Mackness B, Fuller T, Liu X, et al.
Commun Biol
. 2022 Oct;
5(1):1157.
PMID: 36310321
Immunization based antibody discovery is plagued by the paucity of antigen-specific B cells. Identifying these cells is akin to finding needle in a haystack. Current and emerging technologies while effective,...
3.
Jung J, Mundle S, Ustyugova I, Horton A, Boutz D, Pougatcheva S, et al.
J Clin Invest
. 2021 Jul;
131(13).
PMID: 34196304
Seasonal influenza vaccination elicits a diminished adaptive immune response in the elderly, and the mechanisms of immunosenescence are not fully understood. Using Ig-Seq, we found a marked increase with age...
4.
Prabakaran P, Rao S, Wendt M
MAbs
. 2021 May;
13(1):1924347.
PMID: 33947305
Animal-derived antibody sources, particularly, transgenic mice that are engineered with human immunoglobulin loci, along with advanced antibody generation technology platforms have facilitated the discoveries of human antibody therapeutics. For example,...
5.
Zhang R, Prabakaran P, Yu X, Mackness B, Boudanova E, Hopke J, et al.
MAbs
. 2021 Apr;
13(1):1904546.
PMID: 33899674
Hybridoma technology has been valuable in the development of therapeutic antibodies. More recently, antigen-specific B-cell selection and display technologies are also gaining importance. A major limitation of these approaches used...
6.
Prabakaran P, Glanville J, Ippolito G
Front Immunol
. 2020 Jul;
11:1344.
PMID: 32714328
No abstract available.
7.
Prabakaran P, Chowdhury P
Cell Rep
. 2020 Jul;
31(13):107831.
PMID: 32610132
Human antibody repertoire data captured through next-generation sequencing (NGS) has enabled deeper insights into B cell immunogenetics and paratope diversity. By analyzing large public NGS datasets, we map the landscape...
8.
Qiu Y, Stegalkina S, Zhang J, Boudanova E, Park A, Zhou Y, et al.
J Virol
. 2019 Dec;
94(6).
PMID: 31826999
The discovery of potent and broadly protective influenza virus epitopes could lead to improved vaccines that are resistant to antigenic drift. Here, we describe human antibody C585, isolated from a...
9.
Li W, Prabakaran P, Chen W, Zhu Z, Feng Y, Dimitrov D
Antibodies (Basel)
. 2019 Sep;
5(3).
PMID: 31558000
Monoclonal antibodies (mAbs) are the fastest-growing biological therapeutics with important applications ranging from cancers, autoimmunity diseases and metabolic disorders to emerging infectious diseases. Aggregation of mAbs continues to be a...
10.
Wu Y, Xue J, Wang C, Li W, Wang L, Chen W, et al.
J Virol
. 2019 Aug;
93(20).
PMID: 31375583
Early human immunodeficiency virus type 1 (HIV-1) treatment during the acute period of infection can significantly limit the seeding of viral reservoirs and modify the course of disease. However, while...